V175 and V175A vaccines in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human trial evaluates the safety and tolerability of the RSV multivalent vaccines V175 and V175A in healthy adults aged 18-49 or 60-84. Participants are randomized to receive V175, V175A, a control vaccine, or placebo and are closely monitored for adverse events. The study uses standard vaccine safety assessments and follow-up to determine how the vaccines behave in humans. Enrollment targets adults across two age ranges to explore any differences in response by age group. The trial is sponsored by Merck Sharp & Dohme LLC and is conducted at two sites in Australia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Is in good health
* Is an individual of any sex/gender, from 18 years to 49 years of age inclusive, or 60 years to 84 years of age inclusive
* Has a body mass index between 18 and 35 kg/m\^2, inclusive

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has a history of cancer (malignancy)
* Has any known or suspected autoimmune disease or immunosuppressive condition, acquired or congenital
* Has a history of Guillain-Barré Syndrome

Where it's running

• Nucleus Network ( Site 0002)
  Brisbane, Queensland, Australia Recruiting
• Nucleus Network ( Site 0001)
  Melbourne, Victoria, Australia Recruiting

Study contacts

• Study coordinator: Toll Free Number
• Email: Trialsites@msd.com
• Phone: 1-888-577-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reducing unnecessary antibiotic use in children with respiratory infections

  This study is testing whether using a new support system in hospitals can help reduce unnecessary antibiotic prescriptions for kids with respiratory infections like pneumonia and bronchiolitis.

  Recruiting Vanderbilt University Medical Center · Oakland, California and 2 other locations · NCT06788093

• Using MeMed BV to help manage lower respiratory infections in emergency settings

  This study is testing if the MeMed BV test can help doctors decide when to use antibiotics for adults with lower respiratory infections in emergency settings.

  Recruiting at 6 sites MeMed Diagnostics Ltd. · Jacksonville, Florida and 9 other locations · NCT05762302

• DAS181 treatment for lower respiratory tract infections in immunocompromised patients

  This study is testing if a new treatment called DAS181 can help immunocompromised patients with lower respiratory infections caused by the parainfluenza virus and severe COVID-19 feel better.

  Recruiting at 19 sites Phase 3 Ansun Biopharma, Inc. · Duarte, California and 27 other locations · NCT03808922

• Optimising Antibiotic Use for Paediatric LRTIs in Africa

  This study tests whether using point-of-care CRP tests together with the PREPARE score can safely reduce antibiotic use in infants aged 2–24 months with lower respiratory infections in a Johannesburg hospital.

  Recruiting University of Witwatersrand, South Africa · Johannesburg, Gauteng · NCT07841691

• Respiratory infections in newborns and children up to five years

  This project will follow newborns in Colombia and Panamá through age five to see how often respiratory infections happen, which germs cause them, and how those infections affect long-term lung health.

  Recruiting at 2 sites Centro de Estudios en Infectogía Pediatrica · Cali, Valle del Cauca Department and 1 other locations · NCT07249996

• Confirming and collecting more data on Buccalin® tablets for preventing recurrent lower respiratory tract infections

  This trial will test whether Buccalin® gastro-resistant tablets can prevent recurrent lower respiratory tract infections in adults who have had multiple infections.

  Recruiting at 3 sites Phase 4 Laboratorio Farmaceutico SIT srl · Alessandria and 9 other locations · NCT06736288

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.